Abaloparatide Real‐World Patient Experience Study

Abstract

Despite the availability of various osteoporosis treatments, adherence remains suboptimal. One contributing factor may be patient experience with therapy. This US, multicenter, combined retrospective chart review and patient questionnaire study included postmenopausal women at high risk for fracture and is the first study to describe real‐world patient experience with abaloparatide (ABL) injection. Eight geographically diverse secondary care sites in the United States participated ( n = 193). Mean ± SD age was 67.4 ±8.62 years. Most patients (86%) were satisfied with the ABL regimen, especially with ease of preparation (82%), ease of storage (87%), and storage convenience (89%), an attribute 83% of the patients thought was important. The majority of patients reported complete satisfaction with the ABL regimen allowing for their ability to conduct daily activities (85%) and convenience to fit into their daily schedule (84%). All reported taking ABL as directed, by injection in the lower abdomen, and 83% of patients reported medium or high adherence. Patients were satisfied with the needle size (76% completely satisfied), and 93% reported never deliberately missing a dose. Although injecting medication (18%) and higher out‐of‐pocket costs (17%) were deemed the most bothersome attributes, the majority (69%) noted their healthcare team understands how osteoporosis impacts their lives. In multivariable analyses, ease of preparation (OR = 2.62; 95% CI, 1.01–6.81; p = 0.048) and fracture history (OR = 1.72; 95% CI, 1.03–2.86; p = 0.037) were significantly associated with overall satisfaction. Ease of preparation was a predictor of higher satisfaction with treatment convenience (coefficient = 13.60; 95% CI, 8.08–19.12; p = 0.00). Remembering to take the medication was a significant predictor of self‐reported adherence (OR = 16.66; 95% CI, 3.30–84.24; p = 0.001). In conclusion, the majority of patients were satisfied with ABL and found it convenient/easy to prepare and store. High self‐reported adherence may be associated with positive patient experience including ease of use and adequate support from healthcare providers. © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.

Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States

“…Recently, Cosman et al [ 59 ] confirmed the real-world effectiveness of ABL versus TPTD on the nonvertebral fracture incidence using data from the US administrative claims database study. Another study [ 60 ] reported that most women were satisfied with ABL and found it convenient/easy to prepare and store. Further studies assessing preference and satisfaction to ABL in men with osteoporosis, as well as data on real-world effectiveness in this population would be of interest.…”

Skin in the Game?

“…( 2,12 ) Although anabolic agents produce a larger impact on BMD and fracture resistance than antiresorptive agents, ( 1,2,12 ) many patients are reluctant to take injectable medications, and additional approaches are required to make it easier for patients to receive these highly effective therapies. ( 2‐4 ) The data presented in the current study suggest that transdermal abaloparatide is a viable clinical option with good efficacy and safety and should be developed further for the management of high‐ and very high‐risk patients with osteoporosis.…”

“…M ultiple recent studies have confirmed that osteoanabolic agents reduce fractures earlier and to a greater extent than antiresorptive agents (1,2) ; however, clinical use is limited by the need for injection. (3,4) Multiple prior attempts at transdermal or oral delivery failed for a variety of reasons, and the lack of noninjectable anabolic regimens is one of the greatest gaps in the osteoporosis treatment armamentarium. To that end, the current issue of JBMR includes a noninferiority trial (5) that randomized 511 women with osteoporosis to receive 1 year of treatment with transdermal abaloparatide 300 μg/day or standard subcutaneous abaloparatide 80 μg/day, previously demonstrated to be an effective and safe osteoanabolic medication in the pivotal Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE; 6).…”

Abaloparatid – eine neue osteoanabole Therapieoption für die Osteoporose bei postmenopausalen Frauen

“…In der Analyse unerwünschter kardialer Ereignisse zeigte sich kein Unterschied zwischen Abaloparatid und Teriparatid [52]. Eine weitere retrospektive, nach der Zulassung in den USA durchgeführte Untersuchung ergab eine hohe Behandlungszufriedenheit der Patientinnen, die mit einer hohen Therapieadhärenz einher ging [54].…”